Towards harmonization of directly measured free 25-hydroxyvitamin D using an enzyme-linked immunosorbent assay

Christopher T. Sempos1,2 · Ernst Lindhout3 · Nicolas Heureux4,5 · Michel Hars4 · Damon A. Parkington6 · Emily Dennison7 · Ramón Durazo-Arvizu8 · Kerry S. Jones6 · Stephen A. Wise1

Received: 20 May 2022 / Revised: 19 August 2022 / Accepted: 31 August 2022 © The Author(s) 2022

Abstract

The majority of circulating 25-hydroxyvitamin D (25(OH)D) is protein bound and perhaps less available than the free fraction of 25(OH)D; therefore, researchers have proposed that the measurement of free 25(OH)D in human serum may be a better indicator of vitamin D health status than total 25(OH)D. The availability of a new enzyme-linked immunosorbent assay (ELISA) for the determination of free 25(OH)D provides a method for direct measurement of the low levels of non-protein bound 25(OH)D. As an initial step towards harmonization of measurements of free 25(OH)D, the ELISA was used to measure free 25(OH)D in three existing Standard Reference Materials (SRMs): SRM 972a Vitamin D Metabolites in Frozen Human Serum, SRM 2973 Vitamin D Metabolites in Frozen Human Serum (High Level), and SRM 1949 Frozen Prenatal Human Serum. Target values for free 25(OH)D in the nine SRM serum pools, obtained by combining the results from two laboratories, ranged from 3.76 ± 0.36 to 10.0 ± 0.58 pg/mL. Of particular significance is the assignment of free 25(OH)D target values to SRM 1949, which consists of four serum pools from non-pregnant female donors of reproductive age and pregnant women in each of the three trimesters and which also has values assigned for vitamin D binding protein, which increases during pregnancy. The availability of target values for free 25(OH)D in these SRMs will allow researchers to validate new analytical methods and to compare their results with other researchers as an initial step towards harmonization of measurements among different studies and laboratories.

Keywords Free 25-hydroxyvitamin D · Enzyme-linked immunosorbent assay (ELISA) · Standard Reference Materials (SRMs) · Total 25-hydroxyvitamin D · Vitamin D binding protein

Introduction

Because of the importance of vitamin D in human health and development, in either the D2 (ergocalciferol) or D3 (cholecalciferol) form, testing for vitamin D in human serum has become routine to diagnose and monitor deficiency. The major circulating form of vitamin D and the primary marker of vitamin D status is 25-hydroxyvitamin D [25(OH)D], which is defined as the sum of 25-hydroxyvitamin D2 [25(OH)D2] and 25-hydroxyvitamin D3 [25(OH)D3]. Measurements of 25(OH)D are typically performed using a ligand binding assay, which responds to both 25(OH)D2 and 25(OH)D3 and thereby provides total 25(OH)D, or using liquid chromatography–tandem mass spectrometry (LC–MS/MS), which measures the 25(OH)D2 and 25(OH)D3 individually. Recent reviews [1–5] have discussed the challenges and difficulties in assessing vitamin D status, and recent studies [6–11] have demonstrated the variability of results among different 25(OH)D assays.
Like other steroid hormones, circulating 25(OH)D is primarily bound to proteins, with 85% to 90% strongly bound to vitamin D binding protein (VDBP), a specific transport protein for vitamin D; 10% to 15% is loosely bound to serum albumin; and only 0.02% to 0.04% exists in a free, unbound form [12–14]. Recent studies have suggested that the measurement of free 25(OH)D may be a better indicator of vitamin D status than the total 25(OH)D content [14–16], and several reviews have discussed the basis of these conclusions [12, 13, 15, 17, 18].

Methods for the determination of 25(OH)D have been available since the 1970s; however, methods for the determination of free 25(OH)D were first described in the 1980s based on centrifugal ultrafiltration using ³H-labeled 25(OH)D₃ and ¹⁴C-labeled glucose. However, the method was not used extensively because it is time-consuming and expensive [19, 20]. Using affinity constants determined from centrifugal ultrafiltration measurements, Bikle et al. [19] proposed a calculation method in 1986 to determine free 25(OH)D using the measured total 25(OH)D, VDBP, and albumin concentrations and the estimated affinity constants between 25(OH)D and VDBP and albumin. In the early 2010s, an enzyme-linked immunosorbent assay (ELISA) was developed [21] and became commercially available for the direct measurement of free 25(OH)D. The ELISA is based on monoclonal anti-25(OH)D antibodies and uses a specific incubation buffer that enables the capture of the free fraction of 25(OH)D only [21]. The ELISA was validated and compared with the dialysis technique using 15 samples with a regression line slope of 0.992 and $R^2 = 0.737$ [21]. This ELISA is currently the only commercially available assay for free 25(OH)D, and it has been used for the direct determination of free 25(OH)D in numerous studies since 2013 as documented in a 2018 review by Tsuprykov et al. [18], where the authors summarized 54 original papers reporting measurements of free 25(OH)D from 1984 to 2017 using either dialysis (4%), calculation (65%), or ELISA (31%) methods. In 2020, Wang et al. [22] reported using a method based on preparation using an ultrafiltration tube, derivatization with PTAD, and finally separation and detection by LC–MS/MS for the assessment of free 25(OH)D. Based on a vitamin D workshop held in 2016 reported by Bikle et al. [15], a clear need for standardization of measurements of VDBP and free 25(OH)D was identified.

To assist in standardization of measurements of 25(OH)D among laboratories and over time, the Office of Dietary Supplements at the National Institutes of Health (NIH-ODS) organized the Vitamin D Standardization Program (VDSP) in 2010 [23, 24], a collaboration among NIH-ODS, the National Institute of Standards and Technology (NIST), the Centers for Disease Control and Prevention (CDC), and national survey laboratories in several countries. A reference measurement system has been established that includes reference measurement procedures (RMPs) at NIST [25, 26], Ghent University [27], and CDC [28]; NIST Standard Reference Materials® (SRMs) [29–31]; the CDC Vitamin D Standardization – Certification Program (VDSCP) [32]; and collaborations with two accuracy-based proficiency testing/external quality assessment (PT/EQA) programs, i.e., the US College of American Pathologists (CAP) accuracy-based vitamin D (ABVD) program [33] and the UK-based Vitamin D External Quality Assessment Scheme (DEQAS) [34, 35].

In 2009, NIST issued the first frozen serum matrix SRM for the determination of vitamin D metabolites including 25(OH)D₂, 25(OH)D₃, and 3-epi-25-hydroxyvitamin D₃, i.e., SRM 972 Vitamin D in Frozen Human Serum with four serum pools with different levels of the metabolites [29]. When the inventory of SRM 972 was exhausted in 2011, an improved SRM 972a Vitamin D Metabolites in Frozen Human Serum was developed again with four different serum pools representing different levels of metabolites [30]. In 2017, SRM 2973 Vitamin D Metabolites in Frozen Human Serum (High Level) was released consisting of one serum pool with a high level of 25(OH)D₃ (39.4 ng/mL) [31]. In addition to the three metabolites with certified values in SRM 972a, SRM 2973 also had values assigned for 24R,25-dihydroxyvitamin D₃, and values for this metabolite were also added to SRM 972a at this time. Recently, a unique SRM was produced with serum from female donors of reproductive age who were either not pregnant or pregnant in each of the three trimesters, i.e., SRM 1949 Frozen Prenatal Human Serum [36]. Intended primarily for the determination of thyroid hormones, SRM 1949 also has values assigned for 25(OH)D₂, 25(OH)D₃, 3-epi-25-hydroxyvitamin D₃, and VDBP. These SRMs have found widespread use within the vitamin D testing and research community during the past decade for method development and validation and as control materials for routine testing with over 4500 units distributed to hospital/clinical centers, university, commercial testing, and government laboratories [24].

The components of the reference measurement system for total 25(OH)D as described above follow the recommendations established for harmonization of clinical laboratory measurement procedures [37–40]. However, at present, there is no reference measurement system in place or harmonization efforts underway regarding the measurement of free 25(OH)D. As a first step towards harmonization of measurements of free 25(OH)D, the goal of this study was to determine target values for free 25(OH)D using the ELISA method in existing SRMs used for the determination of vitamin D metabolites. With the availability of target values for free 25(OH)D in these SRMs, laboratories can use these SRMs as controls to assure the quality of their measurements and to validate new methods for determination of free 25(OH)D.
Experimental

SRMs evaluated

Three NIST SRMs with values assigned for 25(OH)D2, 25(OH)D3, and total 25(OH)D were evaluated for the content of free 25(OH)D. SRM 972a Vitamin D Metabolites in Frozen Human Serum (3 units, 1 vial per level) [30] and 2973 Vitamin D Metabolites in Frozen Human Serum (High Level) (2 units, 2 vials per level) [31] were provided by NIST and shipped on dry ice to the two participating laboratories. SRM 1949 Frozen Human Prenatal Serum (2 units, 2 vials per level) [36] was purchased from NIST and shipped on dry ice to the two participating laboratories. The SRMs were then stored at −70 °C at each laboratory until analyzed.

Single-donor samples evaluated and selection of laboratories for the evaluation of SRMs

Prior to this study, an interlaboratory comparison study of the performance of the free 25(OH)D ELISA was conducted among nine laboratories using the ELISA to determine free 25(OH)D. Forty single-donor samples were analyzed from a 50 single-donor sample set used in an earlier interlaboratory comparison exercise for the determination of total 25(OH)D described in Wise et al. [6] with values for total 25(OH)D ranging from 6.5 to 61.1 ng/mL. The results of the analysis of these samples for the determination of 25(OH)D2 and 25(OH)D3 using the NIST reference measurement procedures [25] were reported previously [6]. These 40 samples were analyzed for the determination of free 25(OH)D at the Nutritional Biomarker Laboratory, Medical Research Council (MRC) Epidemiology Unit at the University of Cambridge (Cambridge, UK), using the approach described below. The results from the interlaboratory comparison informed the selection of the laboratories for the evaluation of SRMs in the study reported here.

Directly measured free 25(OH)D procedures

Two laboratories, Future Diagnostics (Wijchen, The Netherlands) and Nutritional Biomarker Laboratory (NBL), MRC Epidemiology Unit at the University of Cambridge (Cambridge, UK), analyzed the SRM samples using the DIAsource Free 25OH Vitamin D ELISA assay. The SRM samples were run on each of 3 days with two runs per day and two replicates per run (i.e., 3 days × 2 runs/day × 2 replicates per run = 12 determinations per each level of each SRM). Only one SRM vial was used per day to avoid any potential freeze/thaw stability concerns.

The free 25(OH)D ELISA is based on a two-step immunoassay performed in a microtiter plate. During the first step, free 25(OH)D2 and 25(OH)D3 bind with the anti-vitamin D antibody coated on the bottom of the microtiter plate wells. After washing, a fixed amount of biotinylated 25(OH)D is added to each well to react with the unoccupied antibody binding sites. After washing to remove unbound biotinylated 25(OH)D, streptavidin–peroxidase conjugate is added, and the bound enzyme is quantified colorimetrically [21].

Both laboratories followed the manufacturer’s instructions [21] for measurement of free 25(OH)D using the DIAsource assay. DIAsource Free 25OH Vitamin D ELISA assay short instructions are as follows (KAPF1991, DiaSource ImmunoAssays S.A., Louvain-la Neuve, BE). Add 90 μL sample diluent to the wells. Transfer 10 μL calibrator, control, or sample in duplicate into the appropriate well of the microtiter plate. Incubate the plate for 90 min at 37 °C while shaking at 650 rpm. Wash the plate 3 times with wash buffer. Add 100 μL Biot-VitD reagent to the wells. Incubate the plate for 30 min at 37 °C while shaking at 650 rpm. Wash the plate 3 times with wash buffer. Add 100 μL streptavidin-HRP reagent to the wells. Incubate the plate for 20 min at 37 °C while shaking at 650 rpm. Wash the plate 3 times with wash buffer. Add 100 μL substrate reagent to the wells. Incubate the plate for 15 min at room temperature while stationary and protected from light. Add 100 μL stop reagent to each well. Read the plate at 450 nm within 5 min. The information regarding instruments, calibrators, and instrument controls used by both laboratories are provided in Tables S1, S2, and S3 (Supplementary Information), respectively, and are described briefly below.

Nutritional Biomarker Laboratory (NBL), University of Cambridge

The free 25(OH)D ELISA was performed according to the manufacturer’s instructions by a single analyst. Incubation and shaking were performed with a BMG THERMOstar (BMG Labtech Ltd., UK) and washing with a Thermo Wellwash (Thermo Fisher Scientific, UK). Results were read using a Thermo Multiskan (Thermo Fisher Scientific, UK).

Future Diagnostics

The free 25(OH)D ELISA was performed according to the manufacturer’s instruction by three different analysts. A Thermo iEMS shaker incubator (Thermo Scientific, USA) was used for the incubation, washing was done using a Biotek elx50, and absorption values were measured using a Biotek elx800 plate reader (Biotek, USA).
**Statistical methods**

All data analyses were conducted using CBStat 5.1 (Copyright by Kristian Linnet, Ordup Have 15, DK-2920 Charlottenlund, Denmark). Paired $t$ test was used to test for significant differences between Future Diagnostics and NBL Cambridge determinations for day, run, and duplicate. Mean paired difference over day, run, and duplicate was calculated as the NBL Cambridge determination minus the Future Diagnostics determination. Ordinary least squares regression analysis was used to compare mean values for each SRM level ($n=9$).

**Table 1** National Institute of Standards and Technology (NIST) Standard Reference Materials (SRM®) with vitamin D metabolite assigned values and uncertainty used in this study

| SRM samples       | Serum vitamin D metabolite* (ng/mL) | Vitamin D binding protein (μg/mL) |
|-------------------|-------------------------------------|----------------------------------|
|                   | 25(OH)D$_2$ Mean Uncertainty        | 25(OH)D$_3$ Mean Uncertainty     | Total 25(OH)D Mean Uncertainty |
|                   | Mean Uncertainty                    | Mean Uncertainty                 | Mean Uncertainty               | Mean Uncertainty               |
| SRM 972a level 1  | 0.54 0.06                           | 28.8 1.1                         | 29.3 1.1                       | NR$^b$ NR                     |
| SRM 972a level 2  | 0.81 0.06                           | 18.1 0.4                         | 18.9 0.4                       | NR$^b$ NR                     |
| SRM 972a level 3  | 13.2 0.3                            | 19.8 0.4                         | 33.0 0.5                       | NR$^b$ NR                     |
| SRM 972a level 4  | 0.55 0.10                           | 29.4 0.9                         | 30.0 0.9                       | NR$^b$ NR                     |
| SRM 2973          | 0.65 0.02                           | 39.4 0.8                         | 40.1 0.8                       | NR$^b$ NR                     |
| SRM 1949 NP$^c$   | 0.278 NR                            | 24.98 0.28                       | 25.3$^d$ NR                    | 211.5 2.8                     |
| SRM 1949 1T$^c$   | 1.20 0.05                           | 26.01 0.22                       | 27.2$^d$ NR                    | 286.7 3.8                     |
| SRM 1949 2T$^c$   | 0.514 0.037                         | 30.00 0.50                       | 30.5$^d$ NR                    | 349.7 4.3                     |
| SRM 1949 3T$^c$   | 0.897 0.057                         | 29.43 0.41                       | 30.3$^d$ NR                    | 383.4 5.1                     |

*Certified values in bold type; reference values in normal type. Uncertainties for certified and reference values are not equivalent; see SRM Certificate of Analysis (COA) for complete description of the uncertainties of certified and reference values. To convert ng/mL to nmol/L, multiply 25(OH)D$_2$ concentration by 2.423 and 25(OH)D$_3$ concentration by 2.496

$^b$NR, not reported

$^c$NP, non-pregnant; 1T, 1st trimester of pregnancy; 2T, 2nd trimester of pregnancy; and 3T, 3rd trimester of pregnancy

$^d$Values calculated for this study and not assigned by NIST on the SRM COA
Results and discussion

Interlaboratory comparison and selection of laboratories for the evaluation of SRMs

For the interlaboratory comparison study conducted among nine laboratories using the ELISA to determine free 25(OH)D in a set of 40 single-donor samples [41], overall %CVs for the individual laboratories ranged from 2.8 to 22% with only the assay manufacturer laboratory (Future Diagnostics) and NBL Cambridge achieving %CVs below 4%. The results obtained by Future Diagnostics were considered to be the benchmark, and bias compared to the Future Diagnostics results ranged from 1.3 to 29% with only two laboratories achieving a bias below 5% [41]. The results of this interlaboratory study indicated a need for improvement among laboratories in using this ELISA for the determination of free 25(OH)D. Based on the results of the interlaboratory comparison study, NBL Cambridge and Future Diagnostics were selected to analyze the SRM suite to assign target values for free 25(OH)D using the ELISA.

The NBL Cambridge results for the determination of free 25(OH)D in the 40 single-donor samples are summarized in Table S4. Similar results from the analysis of the same samples by Future Diagnostics are provided in Table S5. These results illustrate the repeatability achievable when using the ELISA. A plot of the free 25(OH)D (NBL Cambridge) concentration versus the NIST Total 25(OH)D in the 40 single-donor samples is shown in Fig. 1, and a similar plot using the Future Diagnostics results for free 25(OH)D is provided in Figure S1 (Supplementary Information).

| Laboratory | Day | Run | Rep | Free 25(OH)D (pg/mL) |
|------------|-----|-----|-----|---------------------|
| 1 1 1 1    | 7.750 | 5.341 | 8.261 | 8.034 | 9.742 | 6.222 | 4.331 | 3.471 | 3.483 |
| 1 1 2 1    | 8.148 | 5.164 | 7.313 | 7.528 | 9.815 | 6.133 | 4.677 | 4.566 | 3.681 |
| 1 2 2 1    | 6.966 | 4.991 | 8.191 | 8.401 | 10.263 | 6.171 | 3.771 | 3.986 | 3.288 |
| 1 2 2 2    | 7.917 | 4.210 | 7.691 | 8.442 | 10.479 | 6.564 | 5.004 | 5.242 | 4.288 |
| 1 2 1 1    | 7.579 | 5.898 | 8.893 | 8.326 | 10.372 | 6.230 | 4.952 | 3.465 | 3.972 |
| 1 2 1 2    | 7.841 | 5.186 | 7.538 | 7.700 | 9.678 | 6.437 | 5.087 | 4.668 | 3.982 |
| 1 2 2 1    | 7.354 | 5.694 | 8.373 | 8.394 | 9.501 | 6.680 | 4.755 | 4.406 | 3.450 |
| 1 2 2 2    | 7.807 | 4.975 | 7.967 | 8.411 | 9.840 | 6.368 | 4.935 | 4.840 | 3.847 |
| 1 3 1 1    | 8.143 | 5.208 | 8.187 | 8.038 | 9.535 | 6.001 | 4.987 | 4.104 | 4.013 |
| 1 3 1 2    | 7.655 | 4.185 | 7.096 | 7.096 | 9.264 | 5.955 | 4.875 | 4.783 | 3.392 |
| 1 3 2 1    | 7.783 | 5.083 | 8.057 | 7.765 | 9.866 | 6.145 | 4.840 | 4.051 | 3.577 |
| 1 3 2 2    | 9.385 | 4.847 | 8.485 | 7.383 | 9.631 | 6.532 | 4.948 | 4.440 | 3.846 |
| 1 1 1 1    | 7.421 | 4.817 | 7.923 | 7.470 | 10.022 | 6.161 | 4.610 | 4.116 | 3.712 |
| 1 1 2 1    | 6.800 | 4.408 | 7.193 | 8.040 | 9.683 | 5.746 | 4.458 | 4.375 | 3.826 |
| 1 2 1 1    | 8.704 | 5.788 | 8.302 | 8.665 | 10.995 | 6.667 | 5.216 | 5.360 | 4.359 |
| 1 2 2 1    | 8.472 | 5.223 | 8.283 | 8.892 | 11.704 | 6.740 | 5.795 | 5.066 | 4.271 |
| 1 2 2 2    | 8.613 | 4.719 | 7.230 | 7.680 | 9.231 | 5.985 | 4.441 | 3.891 | 2.750 |
| 2 1 2 1    | 7.168 | 3.960 | 7.168 | 7.116 | 9.886 | 5.397 | 4.108 | 4.101 | 3.553 |
| 2 2 1 1    | 7.177 | 4.719 | 7.324 | 7.497 | 9.458 | 5.534 | 4.360 | 4.145 | 3.600 |
| 2 2 2 1    | 7.063 | 4.363 | 6.799 | 7.344 | 9.609 | 5.504 | 4.350 | 4.472 | 3.955 |
| 2 3 1 1    | 8.181 | 5.231 | 8.525 | 8.716 | 10.904 | 6.371 | 4.685 | 4.497 | 3.732 |
| 2 3 2 1    | 7.348 | 3.435 | 7.765 | 7.668 | 10.215 | 6.392 | 4.878 | 4.497 | 3.711 |
| 2 3 1 2    | 7.524 | 5.014 | 7.807 | 7.708 | 10.120 | 5.676 | 4.630 | 4.328 | 3.785 |
| 2 3 2 2    | 7.643 | 4.616 | 7.545 | 7.189 | 10.134 | 5.950 | 4.161 | 4.779 | 4.293 |

Non-pregnant, 1st trimester, 2nd trimester, and 3rd trimester

1, Nutritional Biomarker Laboratory (NBL), Cambridge; and 2, Future Diagnostics Laboratory

Rep, replicate

dTo convert pg/mL to pmol/L, multiply by 2.496

Towards harmonization of directly measured free 25-hydroxyvitamin D using an enzyme-linked…
Comparison and combination of results from two laboratories

Three NIST SRMs with nine different levels were available with values assigned for 25(OH)D2, 25(OH)D3, total 25(OH)D, and VDBP as summarized in Table 1. Total 25(OH)D concentrations for the nine materials range from 18.9 to 40.1 ng/mL, with 25(OH)D3 ranging from 18.1 to 39.4 ng/mL. For the four levels of SRM 1949, values are assigned for VDBP, which increases in concentration from 211.5 μg/mL in the non-pregnant serum pool to 383.4 μg/mL in the third trimester serum pool. All nine levels of the SRMs were analyzed to determine the content of free 25(OH)D using the ELISA in two laboratories. The individual results (n = 12 for each SRM...
level) from the two laboratories for the determination of free 25(OH)D are provided in Table 2. The paired mean differences between NBL Cambridge and Future Diagnostics measurements were small as shown in Table 3. The results from the two laboratories were combined, and the means and standard deviations are summarized in Table 4. In six of the nine NIST SRM levels, the NBL Cambridge measurements were slightly higher than the Future Diagnostics Solutions measurements. None of the paired differences were statistically significant (p < 0.05) and the 95% confidence limits for the mean difference in every case included zero. A distribution plot of the results from both laboratories for SRM 972...
level 3 is shown in Fig. 2. Similar distribution plots for the remaining SRM samples are provided in Figures S2 to S9 in Supplementary Information. A plot of the least squares regression of the directly measured free 25(OH)D means from the two laboratories is shown in Fig. 3. The regression line with $R^2 = 0.99$ and slope of 0.977 with 95% confidence interval including zero intercept and slope of 1.00 indicate the near perfect correspondence between the two laboratories for the direct measurement of free 25(OH)D. The standardized residual plot for the regression model shown in Figure S10 (Supplementary Information) does not indicate any violation of the regression model assumptions.
The correlation of directly measured free 25(OH)D with the total 25(OH)D content for the nine SRM levels is shown in Fig. 4. The relationship between free 25(OH)D and total 25(OH)D in the three levels in SRM 1949 representing the three pregnancy trimesters is obviously different from the other SRM serum pools as indicated in Fig. 4 (red dots), and the percent free 25(OH)D was lower in pregnancy compared to non-pregnancy samples. This observation may be explained by the higher circulating level of VDBP observed in pregnant compared to non-pregnant women [42–45] in SRM 1949 where VDBP concentration is associated with directly measured free 25(OH)D concentration between non-pregnancy and pregnancy and in the increased VDBP concentration across gestation (Fig. 5) as reported in longitudinal studies during pregnancy [42, 45]. However, Bikle and Swartz [17] suggest that free 25(OH)D may be the same or only slightly lower during pregnancy.

Use of SRMs for harmonization of measurements

The assignment of target values for free 25(OH)D using the ELISA assay in existing SRMs is an initial step towards harmonization and eventual standardization of measurements of free 25(OH)D. These SRMs are available to any researcher for use as control samples or for assigning target values to in-house control materials. The use of these SRMs for reporting free 25(OH)D concentrations in various studies will allow for comparison of results among different laboratories, different studies, and over time. We recommend that users of the ELISA for free 25(OH)D analyze one or more of the SRMs and compare their results with the target values reported in this paper to determine laboratory/assay performance. If the results are biased, users should evaluate whether the assay protocol has been appropriately followed. Results among different laboratories, and different studies can be harmonized using approaches as described previously for 25(OH)D assays [46, 47].

The availability of additional information characterizing these existing SRMs for vitamin D metabolites enhances the value of these materials [48]. In particular, the addition of free 25(OH)D results to SRM 1949 provides valuable information on the effect of changes in VDBP concentration on free 25(OH)D in pregnancy. This information may also be relevant to other pathological conditions associated with changes in VDBP concentration [49] and their effect on vitamin D metabolism.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00216-022-04313-y.

Acknowledgements The authors acknowledge Johanna E. Camara (NIST) for her assistance in the planning of the study and for providing SRM 972a and SRM 2973 for use in the study and Adam J. Kuszak (NIH-ODS) and the NIH-ODS Analytical Methods and Reference Materials (AMRM) Program for supporting the development of reference materials for vitamin D measurements.

Funding KSJ and DAP are supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre (IS-BRC-1215–20041). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the UK Department of Health and Social Care.

Declarations

Competing interests S. A. Wise is an Editor of the journal Analytical and Bioanalytical Chemistry and was not involved in peer reviewing of this manuscript. Several coauthors are employees of the company that produces the assay kit used in this study. There are no financial or nonfinancial competing interests for any of the coauthors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Alexandridou A, Schorr P, Stokes CS, Volmer DA. Analysis of vitamin D metabolic markers by mass spectrometry: recent progress regarding the “gold standard” method and integration into clinical practice. Mass Spectrom Rev. 2021;1:1–41.
2. Aliteri B, Cavalier E, Bhattoo HP, Perez-Lopez FR, Lopez-Baena MT, Perez-Roncero GR, et al. Vitamin D testing: advantages and limits of the current assays. Eur J Clin Nutr. 2020;74(2):231–47.
3. Makris K, Sempos C, Cavalier E. The measurement of vitamin D metabolites: part I-metabolism of vitamin D and the measurement of 25-hydroxyvitamin D. Horm-Int J Endocrinol Metab. 2020;19(2):81–96.
4. Makris K, Sempos C, Cavalier E. The measurement of vitamin D metabolites part II-the measurement of the various vitamin D metabolites. Horm-Int J Endocrinol Metab. 2020;19(2):97–107.
5. Sempos CT, Binkley N. 25-Hydroxvitamin D assay standardization and vitamin D guidelines paralysis. Public Health Nutr. 2020;23(7):1153–64.
6. Wise SA, Camara JE, Sempos CT, Burdette CQ, Hahn G, Nalin F, et al. Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) intercomparison study 2 – part 1 liquid chromatography – tandem mass spectrometry (LC-MS/MS) assays – impact of 3-epi-25-hydroxyvitamin D3 on assay performance. Anal Bioanal Chem. 2022;414:333–49.
7. Wise SA, Camara JE, Sempos CT, Burdette CQ, Hahn G, Nalin F, et al. Interlaboratory comparison of 25-hydroxyvitamin D assays: Vitamin D Standardization Program (VDSP) intercomparison study 2 - part 2 ligand binding assays – impact of 25-hydroxyvitamin D2 and 24R,25-dihydroxyvitamin D3 on assay performance. Anal Bioanal Chem. 2022;414:351–66.
8. Wise SA, Camara JE, Sempos CT, Lukas P, Le Goff C, Peeters S, et al. Vitamin D Standardization Program (VDSP) Intraaboratory study for the assessment of 25-hydroxyvitamin D assay performance. J Steroid Biochem Mol Biol. 2021;212:105917.

9. Elsenberg E, ten Boekel E, Huijgen H, Heijboer AC. Standardization of automated 25-hydroxyvitamin D assays: how successful is it? Clin Biochem. 2017;50(18):1126–30.

10. Garnett E, Li JL, Rajapakse D, Tam E, Meng QH, Devaraj S. Efficacy of two vitamin D immunoassays to detect 25-OH vitamin D$_2$ and D$_3$. Pract Lab Med. 2019;17:4.

11. Bjerg LN, Halgreen JR, Hansen SH, Morris HA, Jorgensen NR. An evaluation of total 25-hydroxyvitamin D assay standardization: where are we today? J Steroid Biochem Mol Biol. 2019;190:224–33.

12. Bikle DD, Malmstroem S, Schwartz J. Current controversies are free vitamin metabolites levels a more accurate assessment of vitamin d status than total levels? Endocrinol Metabol Clin North Amer. 2017;46(4):901–18.

13. Heureux N. Vitamin D testing-where are we and what is on the horizon? In: Makowski GS, editor. Advances in Clinical Chemistry, Vol 78. Advances in Clinical Chemistry. 78. San Diego: Elsevier Academic Press Inc.; 2017. p. 59–101.

14. Tsuprykov O, Buse C, Skoblo R, Hocher B. Comparison of free and total 25-hydroxyvitamin D in normal human pregnancy. J Steroid Biochem Mol Biol. 2019;190:29–36.

15. Bikle D, Bouillon R, Thadhani R, Schoonmakers I. Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status? J Steroid Biochem Mol Biol. 2017;173:105–16.

16. Tsuprykov O, Elitok S, Buse C, Chu C, Kramer BK, Hocher B. Opposite correlation of 25-hydroxy-vitamin D- and 1,25-dihydroxy-vitamin D-metabolites with gestational age, bone- and lipid-biomarkers in pregnant women. Sci Rep. 2021;11(1):10.

17. Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiologcal conditions. Front Endocrinol. 2019;10:12.

18. Tsuprykov O, Chen X, Hocher CF, Skoblo R, Yin LH, Hocher B. Why should we measure free 25(OH) vitamin D? J Steroid Biochem Mol Biol. 2018;180:87–104.

19. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin-D in serum and its regulation by albumin and the vitamin-D-binding protein. J Clin Endocrinol Metab. 1986;63(4):954–9.

20. Bikle DD, Halloran BP, Gee E, Ryzen E, Haddad JG. Free 25-hydroxyvitamin-D levels are normal in subjects with liver-disease and reduced total 25-hydroxyvitamin-D levels. J Clin Invest. 1986;78(3):748–52.

21. Heureux N, Lindhout E, Swinkels L. A direct assay for measuring free 25-hydroxyvitamin D. J AOAC Int. 2017;100(5):1318–22.

22. Wang DC, Yu SL, Zou YT, Zhang YY, Qiu L, Chen LM. Distribution of free 25OHD in elderly population based on LC-MS/MS. J Steroid Biochem Mol Biol. 2020;200:5.

23. Sempos CT, Vesper HW, Phinney KW, Thienpoint LM, Coates PM, VDSP. Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest. 2012;72:32–40.

24. Wise SA, Tai SSC, Burdette CQ, Camara JE, Bedner M, Lippa KA, et al. Role of the National Institute of Standards and Technology (NIST) in support of the vitamin D initiative of the National Institutes of Health, Office of Dietary Supplements. J AOAC Int. 2017;100(5):1260–76.

25. Tai SSC, Bedner M, Phinney KW. Development of a candidate reference measurement procedure for the determination of 25-hydroxyvitamin D$_2$ and 25-hydroxyvitamin D$_3$ in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem. 2010;82(5):1942–8.

26. Tai SSC, Nelson MA. Candidate reference measurement procedure for the determination of (24R),25-dihydroxyvitamin D$_3$ in human serum using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Chem. 2015;87(15):7964–70.

27. Stepan HM, Vanderroost A, Van Uytfanghe K, Thienpoint LM. Candidate reference measurement procedures for serum 25-hydroxyvitamin D$_2$ and 25-hydroxyvitamin D$_3$ by using iso- tope-dilution liquid chromatography-tandem mass spectrometry. Clin Chem. 2011;57(3):441–8.

28. Mineva EM, Schleicher RL, Chaudhary-Webb M, Maw KL, Botelho JC, Vesper HW, et al. A candidate reference measurement procedure for quantifying serum concentrations of 25-hydroxyvitamin D$_2$ and 25-hydroxyvitamin D$_3$ using isotope-dilution liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2015;407(19):5615–24.

29. Phinney KW, Bedner M, Tai SSC, Vamathevan VV, Sander LC, Sharpless KE, et al. Development and certification of a Standard Reference Material for vitamin D metabolites in human serum. Anal Chem. 2012;84(2):956–62.

30. Phinney KW, Tai SSC, Bedner M, Camara JE, Chia RRC, Sander LC, et al. Development of an improved Standard Reference Material for vitamin D metabolites in human serum. Anal Chem. 2017;89(9):4907–13.

31. Tai SSC, Nelson MA, Bedner M, Lang BE, Phinney KW, Sander LC, et al. Development of Standard Reference Material (SRM) 2973 vitamin D metabolites in frozen human serum (high level). J AOAC Int. 2017;100(5):1294–303.

32. CDC. Vitamin D Standardization — Certification Program https://www.cdc.gov/labstandards/vdscp.html Centers for Disease Control and Prevention. Accessed 8 Sept 2022.

33. Erdman P, Palmer-Toy DE, Horowitz G, Hoofnagle A. Accuracy-based vitamin D survey six years of quality improvement guided by proficiency testing. Arch Pathol Lab Med. 2019;143(12):1531–8.

34. Carter GD, Berry J, Durazo-Arvizu R, Gunter E, Jones G, Jones J, et al. Hydroxyvitamin D assays: an historical perspective from DEQAS. J Steroid Biochem Mol Biol. 2018;177:30–5.

35. Burdette CQ, Camara JE, Nalin F, Pritchett J, Sander LC, Carter GD, et al. Establishing an accuracy basis for the Vitamin D External Quality Assessment Scheme (DEQAS). J AOAC Int. 2017;100(5):1277–87.

36. Bogg ASP, Kilpatrick LE, Burdette CQ, Tevis DS, Fultz ZA, Nelson MA, et al. Development of a pregnancy-specific reference material for thyroid biomarkers, vitamin D, and nutritional trace elements in serum. Clin Chem Lab Med. 2021;59(4):671–9.

37. Miller WG, Myers GL, Gantzer ML, Kahn SE, Schonbrun ZA, Nelson MA, et al. Development and certification of a Standard Reference Material (SRM) 2973 vitamin D metabolites in frozen human serum (high level). J AOAC Int. 2017;100(5):1277–87.

38. Boggs ASP, Kilpatrick LE, Burdette CQ, Tevis DS, Fultz ZA, Nelson MA, et al. Development of a pregnancy-specific reference material for thyroid biomarkers, vitamin D, and nutritional trace elements in serum. Clin Chem Lab Med. 2021;59(4):671–9.

39. Myers GL, Miller WG. Challenge to coordinate harmonization activities on an international level. Clin Chem. 2017;63(9):1108–17.

40. Myers GL, Miller WG. The roadmap for harmonization: status of the International Consortium for Harmonization of Clinical Laboratory Results. Clin Chem Lab Med. 2018;56(10):1667–72.

41. Thienpoint LM, Van Uytfanghe K, De Leeuwen AP. Reference measurement systems in clinical chemistry. Clin Chim Acta. 2002;323(1–2):73–87.

42. Sempos C, Bouillon R, Billen J, Gross M, Whitake J, Carlson H, et al. Interlaboratory comparison study of Future Diagnostics kit for protein C. 22nd Vitamin D Workshop, Poster Session I, Board 44, Thursday May 30, 2019, New York.
42. Best CM, Pressman EK, Queenan RA, Cooper E, O’Brien KO. Longitudinal changes in serum vitamin D binding protein and free 25-hydroxyvitamin D in a multiracial cohort of pregnant adolescents. J Steroid Biochem Mol Biol. 2019;186:79–88.
43. Jones KS, Assar S, Prentice A, Schoenmakers I. Vitamin D expenditure is not altered in pregnancy and lactation despite changes in vitamin D metabolite concentrations. Sci Rep. 2016;6:26795.
44. Tsuprykov O, Buse C, Skoblo R, Hocher B. Free 25 (OH) vitamin D, but not total 25 (OH) vitamin D, is strongly correlated with gestational age and calcium in normal human pregnancy. J Bone Miner Res. 2017;32:S323.
45. Zhang JY, Lucey AJ, Horgan R, Kenny LC, Kiely M. Impact of pregnancy on vitamin D status: a longitudinal study. Br J Nutr. 2014;112(7):1081–7.
46. Durazo-Arvizu RA, Tian L, Brooks SPJ, Sarafin K, Cashman KD, Kiely M, et al. The Vitamin D Standardization Program (VDSP) manual for retrospective laboratory standardization of serum 25-hydroxyvitamin D data. J AOAC Int. 2017;100(5):1234–43.
47. Sempos CT, Betz JM, Camara JE, Carter GD, Cavalier E, Clarke MW, et al. General steps to standardize the laboratory measurement of serum total 25-hydroxyvitamin D. J AOAC Int. 2017;100(5):1230–3.
48. Wise SA. What if using certified reference materials (CRMs) was a requirement to publish in analytical/bioanalytical chemistry journals? Anal Bioanal Chem. 2022, in press.
49. Schoenmakers I, Fraser WD, Forbes A. Vitamin D and acute and severe illness: a mechanistic and pharmacokinetic perspective. Nutr Res Rev. 2021;1–16

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.